Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

, ABT

Abbott

$52.15

-0.7 (-1.32%)

08:49
09/28/17
09/28
08:49
09/28/17
08:49

Dexcom price target lowered to $62 from $90 at BMO Capital

BMO Capital analyst JoanneK.Wuensch lowered her price target on Dexcom (DXCM) after Abbott (ABT) received FDA approval for a competing product. The analyst says the approval was unexpected, but she says that Dexcom's product is "materially superior." She thinks that the company's "long-term growth story remains intact," and she keeps an Outperform rating on the shares.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

ABT

Abbott

$52.15

-0.7 (-1.32%)

  • 18

    Oct

DXCM Dexcom
$67.47

-0.45 (-0.66%)

09/28/17
SPHN
09/28/17
NO CHANGE
Target $70
SPHN
Overweight
Abbott Libre dosing claim a 'black swan event' for Dexcom, says Stephens
While Abbott (ABT) receiving FDA approval of it FreeStyle Libre glucose monitor was "fully expected," the apparent dosing claim for adult patients was a "black swan event," said Stephens analyst Chris Cooley, who cut his price target on Dexcom (DXCM) to $70 from $83 after the unexpected news. He keeps an Overweight rating on Dexcom shares, though, as he sees the CY18 outlook as challenged but thinks the company will be able to ultimately re-accelerate top-line growth given the expected clearance of G6 and user preference for accuracy and functional CGM data.
09/28/17
WEDB
09/28/17
NO CHANGE
Target $76
WEDB
Outperform
Dexcom price target lowered to $76 from $85 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Dexcom (DXCM) to $76 from $85 due to Abbott (ABT) obtaining FDA approval of its FreeStyle Libre CGM sooner and with a better label than anticipated. Nonetheless, the analyst reiterates an Outperform rating on Dexcom's shares as he believes the market opportunity is large enough to support more than one company and Dexcom's G5 CGM offers users several unique advantages that will continue to attract new users to its system. Further, Levy believes Dexcom could accelerate its own no-calibration CGM regulatory program and potentially obtain FDA approval by the end of 2018.
09/28/17
ADAM
09/28/17
NO CHANGE
Target $69
ADAM
Buy
Dexcom price target lowered to $69 from $90 at Canaccord
Canaccord analyst Kyle rose lowered his price target on Dexcom (DXCM) to $69 from $90 following the announcement that Abbott (ABT) received FDA PMA approval for its FreeStyle Libre glucose monitoring system. Although the approval was expected, the analyst did not expect the label to include an insulin dosing indication, leading to his price reduction. Rose maintained his Buy rating on Dexcom despite the competitive uncertainty ahead.
09/28/17
LEHM
09/28/17
NO CHANGE
Target $60
LEHM
Equal Weight
Barclays up Abbott target, lowers Dexcom target on Libre approval
Barclays analyst Matthew Taylor says FDA approval of Abbott Laboratories' (ABT) FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adults to make treatment decisions without a fingerstick, came a bit earlier than consensus expectations with a significantly better than expected label as it allows for dosing or a replacement claim. While Dexcom's (DXCM) system is more accurate, has alerts, and a strong fan base, Abbott's entry into the U.S. market with this label could be disruptive, Taylor tells investors in a research note. He believes Libre could be both market expanding for glucose monitoring devices and take share from other players, including Dexcom. Its lower price could also pressure price in the market, Taylor contends. The analyst raised his price target for Overweight-rated Abbott to $60 from $57 and lowered his price target for Equal Weight-rated Dexcom to $60 from $76.
ABT Abbott
$52.15

-0.7 (-1.32%)

TODAY'S FREE FLY STORIES

07:51
02/22/18
02/22
07:51
02/22/18
07:51
General news
Futures pointing to higher open »

Stock futures have…

07:51
02/22/18
02/22
07:51
02/22/18
07:51
Conference/Events
The FCC to hold a commission meeting »

Open Commission Meeting…

07:50
02/22/18
02/22
07:50
02/22/18
07:50
Conference/Events
Federal Reserve Bank of New York President speaks at press briefing »

New York Federal Reserve…

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

07:49
02/22/18
02/22
07:49
02/22/18
07:49
Recommendations
Stamps.com analyst commentary  »

Stamps.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 23

    May

LNKD

Acquired by MSFT

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Conference/Events
Detroit Economic Club to hold a breakfast meeting »

Brenda Meller, Owner and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MCS

Marcus

$26.10

1 (3.98%)

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Earnings
Marcus reports Q4 EPS $1.21, consensus 38c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    May

PHX

Panhandle Oil & Gas

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Initiation
Panhandle Oil & Gas initiated  »

Panhandle Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 11

    Mar

CRM

Salesforce

$114.48

0.13 (0.11%)

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

07:46
02/22/18
02/22
07:46
02/22/18
07:46
Conference/Events
FDA to co-host a workshop »

The FDA, American…

MLNX

Mellanox

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RDHL

RedHill Biopharma

$6.26

0.05 (0.81%)

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Earnings
RedHill Biopharma reports Q4 EPS (26c), consensus (60c) »

Reports Q4 revenue $2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

07:43
02/22/18
02/22
07:43
02/22/18
07:43
Conference/Events
JPMorgan to hold a conference »

Korea Conference will be…

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

ROKU

Roku

$51.10

-0.08 (-0.16%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 21

    Mar

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees Q1 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

AKBA

Akebia

$14.31

0.69 (5.07%)

, CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

07:41
02/22/18
02/22
07:41
02/22/18
07:41
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

AKBA

Akebia

$14.31

0.69 (5.07%)

CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

RDUS

Radius Health

$37.71

-0.51 (-1.33%)

TYME

Tyme Technologies

$3.37

-0.06 (-1.75%)

HCA

HCA Healthcare

$100.35

-0.65 (-0.64%)

ARAY

Accuray

MDRX

Allscripts

$13.57

0.335 (2.53%)

ABEO

Abeona Therapeutics

$11.70

0.1 (0.86%)

SGEN

Seattle Genetics

$54.11

-0.05 (-0.09%)

INSY

Insys Therapeutics

$7.93

0.34 (4.48%)

SPPI

Spectrum

$20.51

0.21 (1.03%)

SPH

Suburban Propane

$24.10

-0.2 (-0.82%)

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

DEPO

Depomed

$7.46

0.07 (0.95%)

KTWO

K2M Group

$19.09

-0.01 (-0.05%)

INOV

Inovalon

$11.68

-1.025 (-8.07%)

IMMU

Immunomedics

$16.38

0.16 (0.99%)

OVID

Ovid Therapeutics

$6.83

-0.2 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 11

    Mar

  • 14

    Mar

  • 01

    May

  • 03

    May

  • 22

    Feb

HSC

Harsco

$16.75

0.45 (2.76%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Earnings
Harsco reports Q4 EPS ex-items 20c, consensus 14c »

Reports Q4 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

WPC

W.P. Carey

$59.53

-0.73 (-1.21%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Hot Stocks
W.P. Carey enters into 18-year triple net lease with Astellas Institute »

W. P. Carey has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

07:40
02/22/18
02/22
07:40
02/22/18
07:40
General news
Fed's Quarles anticipates further gradual tightening »

Fed's Quarles…

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Earnings
Gibraltar Industries sees FY18 adjusted EPS $1.96-$2.08, consensus $1.81 »

Gibraltar is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$109.06

-1.92 (-1.73%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Recommendations
Chevron analyst commentary  »

Chevron weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRC

Brady

$38.05

0.1 (0.26%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Brady reports Q2 EPS 8c, may not be compared to consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Gibraltar Industries sees Q1 adjusted EPS 23c-28c, one est. 30c »

For Q1, the company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:37
02/22/18
02/22
07:37
02/22/18
07:37
Earnings
Welltower sees 2018 normalized FFO $3.95-$4.05, consensus $4.20 »

Expects average blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.